Primary Biliary Cholangitis (PBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Primary biliary cholangitis (PBC), once known as primary biliary cirrhosis, is a chronic ailment involving progressive damage, inflammation, and eventual destruction of the liver’s small bile ducts. Bile, a crucial digestive fluid produced by the liver, plays a vital role in processing food and expelling toxins, cholesterol, and aged red blood cells from the body. However, when these bile ducts suffer harm, bile accumulates in the liver, leading to irreversible scarring of liver tissue, a condition known as cirrhosis. Activated CD4 and CD8 lymphocytes drive the continual deterioration of these small and medium-sized bile ducts. In adults experiencing cholestasis (elevated levels of alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT)), suspicions of PBC arise once obstructive jaundice and systemic diseases have been ruled out through abdominal ultrasound. A confirmed diagnosis is made when disease-specific autoantibodies, such as antimitochondrial autoantibodies (AMA titer>1:40) and anti-nuclear autoantibodies (ANA) anti-sp100 and anti-gp210, are detected. Other conditions include autoimmune hepatitis, primary sclerosing cholangitis, alcoholic and non-alcoholic steatohepatitis, and drug-induced hepatotoxicity. The primary goal of treatment is to alleviate symptoms and slow the progression of the disease. Ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg/day effectively improves transplant-free survival, though its impact on fatigue and itching is limited. For patients with insufficient responses (25%-40%), obeticholic acid may be introduced. Cholestyramine is the initial treatment for itching, with rifampin recommended for those intolerant or resistant to it. In patients with normal or near-normal liver biochemistry while on UDCA, their liver transplant-free survival is comparable to that of the general population. Conversely, those with abnormal liver biochemistry on treatment face significantly reduced survival rates. Following a liver transplant, the recurrence of PBC can be as high as 18% at five years and up to 30% at ten years, with risk factors for recurrence still lacking consensus. While hepatocellular carcinoma (HCC) is rare in PBC, non-response to UDCA after a year of therapy and male gender increase the likelihood of developing HCC.
• The prevalence of PBC in the United States has risen substantially, with a 114% increase in men (from 7.7 to 15.4 per 100,000 persons) and a rise from 33.5 to 57.8 per 100,000 persons in women.

Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Primary Biliary Cholangitis (PBC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Primary Biliary Cholangitis (PBC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Primary Biliary Cholangitis (PBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Primary Biliary Cholangitis (PBC), Primary Biliary Cholangitis (PBC) market outlook, Primary Biliary Cholangitis (PBC) competitive landscape, Primary Biliary Cholangitis (PBC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)